How Immunotherapy Could Change Type 1 Diabetes Treatment

New treatments aim to stop the immune system from attacking insulin-producing cells. Researchers are testing immunotherapies at different stages—before diabetes develops, right after diagnosis, and beyond.

Community video — lay discussion, not peer-reviewed research

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cureresearchclinical trial

Key takeaways

Immunotherapies work by reprogramming the immune system to stop or slow attacks on insulin-producing beta cells in the pancreas
These treatments may help people at three different stages: those at risk before diagnosis, newly diagnosed patients, and those further along in the disease
At diagnosis, up to 30% of beta cells may still be alive and potentially salvageable with the right treatment
Identifying people at risk before symptoms appear—through genetic testing or blood markers called autoantibodies—opens a window for prevention or delay

Understanding the Immune System Attack

Type 1 diabetes happens when the immune system mistakenly attacks the beta cells in the pancreas that produce insulin. Instead of protecting against infection, the immune system treats these healthy cells as enemies and destroys them. Immunotherapies represent a new approach: rather than managing blood sugar after the damage is done, they aim to stop or slow the immune attack before—or early after—it causes harm.

Three Windows of Opportunity

Researchers have identified three stages where immunotherapy could make a difference.

**Stage One: Prevention.** Some people carry genetic signals or blood markers called autoantibodies that show their immune system has begun planning an attack, even though they don't yet have diabetes symptoms. At this stage, immunotherapy might prevent the attack from starting or delay the onset of diabetes until later in life.

**Stage Two: Early After Diagnosis.** When someone is newly diagnosed with type 1 diabetes, the immune system hasn't yet destroyed all the beta cells. Research shows that up to 30% of these insulin-producing cells may still be alive. Immunotherapy given at this point could help preserve the remaining cells and maintain some natural insulin production.

**Stage Three: Beyond Early Diagnosis.** Immunotherapies are also being studied in people further along in their type 1 diabetes journey, though the video does not detail outcomes at this stage.

How Immunotherapies Work

Immunotherapies reprogram the immune system by blocking specific killer immune cells that drive the attack on beta cells. This targeted approach differs from older treatments that broadly suppressed the entire immune system. By being more selective, these newer therapies aim to stop the destructive attack while preserving the body's ability to fight genuine infections.

Where Research Stands Now

Diabetes UK and other organizations have been supporting immunotherapy research for years. Scientists are running clinical trials across the UK to test which immunotherapies work and how quickly they can reach people living with or at risk of type 1 diabetes. These trials are essential for understanding which approaches are safe and effective, and for learning which patients benefit most from each treatment.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.